Subscribe To

Price Alert Latest News Economic Calendar News

CELC / Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the 2023 Annual Meeting of the American Association for Cancer Research (AACR), which will be held April 14-19, 2023 in Orlando, Florida. Read More

Demo Live Account See Partner Details

Content Topics

Celcuity

Present

Preclinical

Data

Therapeutic

Effects

Gedatolisib

Gynecological

Cancer

Models

Annual

Meeting

Stock

CELC

Posted: Mar 15 2023, 19:35

Author Name: Accesswire

CELC News

By GlobeNewsWire
November 1, 2023

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted t

By Seeking Alpha
May 15, 2023

Celcuity Inc. (CELC) Q1 2023 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sulliv

By Accesswire
May 8, 2023

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted th

By Seeking Alpha
March 23, 2023

Celcuity Inc. (CELC) Q4 2022 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sull

By Accesswire
March 15, 2023

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted

By Seeking Alpha
November 13, 2022

Celcuity Inc. (CELC) Q3 2022 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke Brian Sulli

By Accesswire
November 3, 2022

Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN/ ACCESSWIRE / November 3, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targete

By Zacks Investment Research
May 30, 2022

Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of t

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.